Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-885-0 | CAS number: 100-74-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2003
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Remarks:
- e.g. study in Japanese language, except for figures, tables and summary, derived NOAEL underestimated
- Justification for type of information:
- The original study report, according to OECD 407, is in Japanese language, although the figures and tables are in English. An English summary is available from the Japanese authorities and an extensive summary is present in the OECD HPV program files. After assessing the tables with results, the derived NOAEL seems to be underestimated.
Data source
Referenceopen allclose all
- Reference Type:
- other: public database
- Title:
- Unnamed
- Year:
- 2 003
- Reference Type:
- other: public database
- Title:
- Unnamed
- Year:
- 2 003
- Report date:
- 2003
- Reference Type:
- grey literature
- Title:
- Unnamed
- Year:
- 2 004
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 005
- Report date:
- 2007
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 4-ethylmorpholine
- EC Number:
- 202-885-0
- EC Name:
- 4-ethylmorpholine
- Cas Number:
- 100-74-3
- Molecular formula:
- C6H13NO
- IUPAC Name:
- 4-ethylmorpholine
- Test material form:
- liquid
- Details on test material:
- - Alternative names of reference substance: Jeffcat NEM; N-ethylmorpholine; 4-ethylmorpholin; Morpholine, 4-ethyl-
- Molecular formula: C6H13NO
- Molecular weight: 115.17
- SMILES notation: CCN1CCOCC1
- InChl: InChI=1/C6H13NO/c1-2-7-3-5-8-6-4-7/h2-6H2,1H3
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: 2901P0
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: The test solution was kept in a refrigerator
- Stability under test conditions: The test solution was prepared and diluted to dosing concentrations by injection solvent every week. The diluted solution was confirmed to be stable for 8 days.
Test animals
- Species:
- rat
- Strain:
- other: Crj:CD(SD)IGS
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Japan, Inc.
- Age at study initiation: 4 weeks old
- Weight at study initiation: day 1 mean weight: males 148.3 g (142.8-156.5 g) and females 126.9 g (120.3-133.7 g)
- Fasting period before study: no data
- Acclimation period: 8 days before use
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test solution was prepared and diluted to dosing concentrations by injection solvent every week. They were kept in a refrigerator. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- GC method. No further data known.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0 (vehicle), 50, 200, 800 mg/kg bw/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 10 at 0 and 800 mg/kg bw/day)
5 at 50 and 200 mg/kg bw/day) - Control animals:
- yes, concurrent vehicle
- Details on study design:
- Recovery group: 0 (vehicle), 800 mg/kg bw/day
Recovery period: 14 days - Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes, daily
DETAILED CLINICAL OBSERVATIONS: Yes, once a week
Functional observations (ambulation, rearing, auditory, visual, proprioceptive stimuli, grip strength) in 4th week of dosing period and 2nd week of recovery period.
BODY WEIGHT: Yes (incl. body weight changes and body weight gain)
On day 1, 2, 4, 8, 11, 15, 18, 22, 25, 28 of dosing period and on day 1, 4, 8, 11, 14 of recovery period
FOOD CONSUMPTION: Yes
On day 1, 8, 15, 22 of dosing period and on day 1 and 8 of recovery period.
HAEMATOLOGY: Yes, at end of dosing period and at the end of the recovery period.
Parameters examined: RBC, hemoglobin, hematocrit, MCV, MCH, MCHC, platelet, PT, APTT, WBC, % of neutrophils-eosinophils-basophils-monocytes-lymphocytes
CLINICAL CHEMISTRY: Yes, at the end of dosing period and at the end of the recovery period.
Parameters examined: total protein, albumin, A/G, BUN, creatinine, glucose, total cholesterol, triglyceride, total bilirubin, inorganic P, Ca, Na, K, Cl, ALP, GPT, GOT, gamma-GTP
URINALYSIS: Yes, on day 23 of dosing period .
Parameters examined: urinary volume, specific gravity, pH, color, turbidity, protein, glucose, ketone, bilirubine, occult blood, urobilinogen, sodium, potassium and chlorine.
Microscopic examination of urinary sediment: red blood cells, crystal, cast, white blood cells, epithelial cells.
ORGAN WEIGHT: Yes - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, at the end of dosing period and at the end of recovery period.
Absolute organ weights: brain, thymus, heart, liver, kidneys, spleen, adrenal glands, testes, epididymides, ovaries.
Macroscopical examination.
HISTOPATHOLOGY: Yes
Organs examined: liver, kidney, spleen, heart, prostate, ovary, lung & bronchus, adrenal gland, stomach, ileum, colon, mesenteric and submandibular lymphnodes, thymus, trachea, brain, spinal cord, sciatic nerve & gastrocnemial muscle, thyroid gland, testis, epididymis, uterus, urinary bladder, bone & marrow of femur, jejunum. - Statistics:
- Barlett's tests were initially performed for body weight, food consumption, hematological examination results, hemostasis examination results, blood chemical examination results, urinalysis results (urine volume and urinary osmolality), organ weight, and relative organ weight. When their values were equal variance on Barlett's tests, Dunnett's multiple comparison tests were performed and the significant difference between dose groups were examined. Fischer's exact tests were performed for pathological examination. Additionally, F-test, Student t-test, Aspin-Welch t-test, chi-square test, Wilcoxon test, and mann-Whitney U-test were also used.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- - Both sexes: No deaths were observed in any of the treatment groups during dosing and recovery period.
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- effects observed, treatment-related
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY:
- Both sexes:
In 200 or 800 mg/kg bw/day group: cage-licking and chewing were observed
In 800 mg/kg bw/day group: Action tremors, decrease in movement, a crouching position, eyelid closure and salivation were observed. In detailed clinical observation, increased incidences of slight irritability, of touch responses vocalization and action tremors were observed. A few females showed intermitted walking and prone position. In the functional test at the 4th week of administration, lower number of rearing was observed in females during the first 30 minuts after administration. Numbers of animals showing no ambulation trend to decrease in both sexes during each testing period. In the recovery period, a high number of rearing was observed in males during the first 30 minutes of observation. No other clinical signs were observed during the recovery period.
BODY WEIGHT AND WEIGHT GAIN:
- Male:
The body weight gains at 800 mg/kg bw/day decreased significantly from day 2 of the administration period to the end of the recovery period.
- Female:
The body weight gains at 800 mg/kg bw/day were lower from day 4 of the administration period to the end of recovery period, and decreased significantly from day 4 to 11, on day 28 of the administration period, and from day 4 to day 14 of the recovery period.
FOOD CONSUMPTION:
- Male:
The food consumption at 800 mg/kg bw/day decreased significantly from day 1 of the administration period to day 1 of the recovery period.
- Female:
The food consumption at 800 mg/kg bw/day decreased significantly from day 1 to 8 of the administration period.
HAEMATOLOGY
after administration period:
- Male:
Reduction of prothrombin time and activated partial thromboplastin time were found at 800 mg/kg bw/day. Although significant reductions for PT were found at 50 and 200 mg/kg bw/day, the author judged that these changes had no toxicological meaning.
- Female:
Although reduction of prothrombin time was found at 50 mg/kg bw/day, the author judged that these changes were non-toxicological. Higher percentage of neutrophil and monocyte and lower percentage of eosinophil and lymphocyte in differential leukocyte ratio, and increase in platelet were found at 800 mg/kg bw/day.
after recovery period:
- Male:
None
- Female:
Increase in platelet was found at 800 mg/kg bw/day.
CLINICAL CHEMISTRY:
after administration period:
- Male:
in 800 mg/kg bw/day group:
Increase in inorganic phosphate, calcium and blood urea nitrogen; decreases in chloride and albumin
- Female:
in 800 mg/kg bw/day group:
Increase in inorganic phosphate, glucose and triglyceride; decreases in chloride, GOT and total bilirubin. GOT was also decreased in 50 and 200 mg/kg bw/d females.
after recovery period:
- Male:
in 800 mg/kg bw/day group:
increases in A/G ratio
- Female:
in 800 mg/kg bw/day group:
decreases in total protein, albumin, glucose.
URINALYSIS:
- Male:
Protein was decreased in 800 mg/kg bw group
- Female:
Keton bodies and urobilinogen was increased and specific gravity was decreased in 800 mg/kg bw group
No effects during recovery period.
ORGAN WEIGHTS
after administration period:
- Male:
in 800 mg/kg bw/day group: decrease in absolute weight of epididymides, increase in relative weight of brain, liver, kidneys, adrenal glands and testes.
- Female:
in 800 mg/kg bw/day group: decrease in absolute weight of brain, increase in absolute weight of liver, increase in relative weights of liver and kidneys
after recovery period:
- Male:
in 800 mg/kg bw/day group: decrease in absolute weight of heart and liver, increase in relative weight of brain
- Female:
in 800 mg/kg bw/day group: increase in relative weight of brain
GROSS PATHOLOGY:
Macroscopically:
No toxicological change was observed
HISTOPATHOLOGY: NON-NEOPLASTIC
after administration period:
- Male:
in 800 mg/kg bw/day group:
Very slight hypertrophy of centrilobular hepatocytes in liver (1/5)
Very slight vacuolation of epithelium in distal and Henle's loop in kidneys (3/5)
- Female:
in 800 mg/kg bw/day group:
Very slight or slight hypertrophy of centrilobular hepatocytes in liver (4/5)
Very slight microgranuloma in liver (1/5)
Very slight and slight vacuolation of epithelium in distal and Henle's loop in kidneys (2/5)
(No. of animal with change/No. of animal tested)
After recovery period:
- Male:
None
- Female:
None
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Remarks:
- disregarded
- Effect level:
- 50 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: This NOAEL was derived by the authors of the study, based on clinical signs (cage licking and chewing) at 200 and 800 mg/kg bw/d. As these clinical signs do not constitute an adverse effect, this NOAEL is disregarded.
- Dose descriptor:
- NOAEL
- Effect level:
- 200 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Based on toxicologically adverse effects at 800 mg/kg bw/d only.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The NOAEL for oral repeated dose toxicity in Cjr:CD(SD)IGS rats is considered to be 50 mg/kg bw/day for both sexes based on cage licking and chewing at 200 and 800 mg/kg bw/day. These clinical signs do not represent a toxicologically adverse effect and are furthermore not mentioned in an OECD 421 study, performed in the same lab with the same rat strain. As relevant adverse effects are observed at 800 mg/kg bw/day only, a NOAEL of 200 mg/kg bw/day is proposed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.